{
    "clinical_study": {
        "@rank": "149899", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.  Determine the bacteriological activity of amithiozone against Mycobacterium\n      avium complex (MAC) pulmonary disease.\n\n      II.  Define the ability of amithiozone to improve clinical outcomes in patients with MAC\n      infection.\n\n      III.  Determine the safety and tolerance of amithiozone with chronic dosing in these\n      patients.\n\n      IV.  Assess the contribution of clarithromycin, streptomycin, rifampin, ethambutol,\n      kanamycin, and amithiozone in the treatment of pulmonary MAC infection."
        }, 
        "brief_title": "Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease", 
        "condition": "Mycobacterium Avium-Intracellulare Infection", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Mycobacterium Infections", 
                "Mycobacterium avium-intracellulare Infection"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: The is a randomized, open label study. All patients receive a core regimen\n      of clarithromycin and streptomycin. Patients are randomized into two treatment arms.  Arm I\n      patients receive rifampin and ethambutol.  Arm II patients receive amithiozone.\n\n      Patients are followed for one year to detect any relapse or other complications.\n\n      Patients not eligible for this randomized study may be entered on a short open label study\n      with amithiozone."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n          -  Progressive pulmonary disease due to Mycobacterium avium complex (MAC) as defined by:\n             Three of more sputum culture(s) positive for MAC Change in serial chest\n             roentgenograms consistent with active mycobacterial disease over a 12 week period No\n             other obvious cause of pulmonary disease\n\n          -  Patients must have organisms that are: Susceptible to amithiozone AND Susceptible or\n             moderately susceptible to the combination of rifampin and ethambutol, and to\n             clarithromycin and streptomycin\n\n        --Prior/Concurrent Therapy--\n\n          -  No likelihood of resectional thoracic surgery within 24 weeks of evaluation\n\n        --Patient Characteristics--\n\n          -  Age: 18 and over\n\n          -  Performance status: Not specified\n\n          -  Hematopoietic: Not specified\n\n          -  Hepatic: Bilirubin less than 3 times normal SGOT/SGPT less than 3 times normal\n             Alkaline phosphatase less than 3 times normal\n\n          -  Renal: Creatinine clearance at least 30 mL/min\n\n          -  Cardiovascular: No New York Heart Association class III or IV heart failure\n\n          -  Other: No optic disease that precludes the use of ethambutol No hypersensitivity to\n             rifampin, ethambutol, clarithromycin, streptomycin, or amithiozone HIV negative Not\n             pregnant or nursing"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "50", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004689", 
            "org_study_id": "199/13311", 
            "secondary_id": [
                "NJCIRM-HS-750", 
                "NJCIRM-FDR000812"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "amithiozone", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "clarithromycin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "ethambutol", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "rifampin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "streptomycin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ethambutol", 
                "Rifampin", 
                "Thioacetazone", 
                "Streptomycin", 
                "Clarithromycin"
            ]
        }, 
        "keyword": [
            "bacterial infection", 
            "immunologic disorders and infectious disorders", 
            "mycobacterium avium infection", 
            "mycobacterium infection", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "National Jewish Health", 
            "last_name": "Charles Arthur Peloquin", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004689"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "National Jewish Health", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "January 1991", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 1999"
    }, 
    "geocoordinates": {}
}